AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11668094 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional information (standard information plus place of injury, number of A&E attendances for injury in previous year, and any information recorded about safety equipment)
Number of subjects: 0
Study 11668094 — intervention group
Group type: EXPERIMENTAL
Intervention: Notifications for selected attendances
Number of subjects: 0
Study 11668094 — intervention group
Group type: COMPARATOR
Intervention: Notifications for all attendances
Number of subjects: 0
Study 9676464 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI with Gd-enhanced FLASH sequence
Number of subjects: 44
Study 9676464 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI with T2-weighted fat saturation technique
Number of subjects: 44
Study 9676464 — intervention group
Group type: COMPARATOR
Intervention: MRI without contrast
Number of subjects: 44
Study 8207699 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandimmune Neoral (180 mg)
Number of subjects: 24
Study 8207699 — intervention group
Group type: COMPARATOR
Intervention: Sandimmune (300 mg)
Number of subjects: 24
Study 2914336 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml.kg‐1 of apple juice given 2.6 +/‐ 0.4 hours preoperatively
Number of subjects: 80
Study 2914336 — intervention group
Group type: COMPARATOR
Intervention: Control group (no apple juice)
Number of subjects: 80
Study 1173614 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 261
Study 31575326 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron (5 mg twice daily) and fluvoxamine (100 mg daily initially followed by 200 mg daily after week 4)
Number of subjects: 108
Study 31575326 — intervention group
Group type: COMPARATOR
Intervention: Placebo and fluvoxamine (100 mg daily initially followed by 200 mg daily after week 4)
Number of subjects: 108
Study 27929709 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system (BTDS)
Number of subjects: 6566
Study 27929709 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine transdermal system (BTDS) and active controls (oxycodone/acetaminophen [OXY/APAP] and hydrocodone/acetaminophen [HCD/APAP])
Number of subjects: 6566
Study 25659147 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and MFGM supplementation (Ex+MFGM)
Number of subjects: 131
Study 25659147 — intervention group
Group type: COMPARATOR
Intervention: MFGM supplementation
Number of subjects: 131
Study 25659147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 25659147 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and placebo (Ex+Plac)
Number of subjects: 131
Study 24046924 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured education pulmonary rehabilitation programme
Number of subjects: 20
Study 24046924 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 20
Study 21106713 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 16
Study 21106713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 18831530 — intervention group
Group type: EXPERIMENTAL
Intervention: Istradefylline 20 mg once daily
Number of subjects: 231
Study 18831530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 16897238 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-fentanyl anesthesia (SF)
Number of subjects: 51
Study 16897238 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl-free sevoflurane anesthesia (S)
Number of subjects: 51
Study 12761422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil prophylaxis at 12.5-15.0 mg/kg at bedtime every night (group I, n=15)
Number of subjects: 33
Study 12761422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil prophylaxis at 12.5-15.0 mg/kg at bedtime every alternate night (group II, n=18)
Number of subjects: 33
Study 12761422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil prophylaxis (both groups)
Number of subjects: 33
Study 12761422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil prophylaxis
Number of subjects: 33
Study 11205194 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily for 4 months
Number of subjects: 0
Study 11205194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8980795 — intervention group
Group type: EXPERIMENTAL
Intervention: Theo-Dur
Number of subjects: 12
Study 8980795 — intervention group
Group type: EXPERIMENTAL
Intervention: Theo-24
Number of subjects: 12
Study 8980795 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanthium
Number of subjects: 12
Study 8980795 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline (IV)
Number of subjects: 12
Study 8511308 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radiation therapy (5 fractions of 2 Gy each)
Number of subjects: 137
Study 8511308 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose radiation therapy (10 fractions of 2 Gy each)
Number of subjects: 137
Study 8511308 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose radiation therapy (5 fractions of 3.5 Gy each)
Number of subjects: 137
Study 8511308 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal antiinflammatory drug (NSAID) use
Number of subjects: 137
Study 8511308 — intervention group
Group type: EXPERIMENTAL
Intervention: High RT dose with short duration (< or = 9 days)
Number of subjects: 137
Study 3551401 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA) with morphine
Number of subjects: 60
Study 3551401 — intervention group
Group type: COMPARATOR
Intervention: Pyrazolone (intramuscularly and intravenously)
Number of subjects: 60
Study 31628574 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural coagulation scenarios
Number of subjects: 20
Study 31628574 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-procedural coagulation parameters (platelet count and fibrinogen level)
Number of subjects: 20
Study 31628574 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation for mesenteric vein thrombosis in liver transplant candidates
Number of subjects: 20
Study 31628574 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation in non-liver transplant candidates with mesenteric vein thrombosis
Number of subjects: 20
Study 28917523 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping with skin convolutions
Number of subjects: 148
Study 28917523 — intervention group
Group type: COMPARATOR
Intervention: Kinesio taping without convolutions (Sham Taping)
Number of subjects: 148
Study 24889273 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisseel/Tissucol
Number of subjects: 316
Study 24889273 — intervention group
Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 316
Study 22672081 — intervention group
Group type: EXPERIMENTAL
Intervention: LM25 therapy (25% insulin lispro, 75% insulin lispro protamine suspension)
Number of subjects: 426
Study 22672081 — intervention group
Group type: COMPARATOR
Intervention: Glargine + insulin lispro therapy
Number of subjects: 426
Study 20920236 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone PR/naloxone PR (n = 292)
Number of subjects: 587
Study 20920236 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone PR (n = 295)
Number of subjects: 587
Study 18772509 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin combined with routine treatment (beta receptor blocker, calcium-channel blocker, long active nitrate)
Number of subjects: 40
Study 18772509 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin combined with routine treatment
Number of subjects: 40
Study 18772509 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (beta receptor blocker, calcium-channel blocker, long active nitrate)
Number of subjects: 40
Study 18772509 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 40
Study 15970103 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil-procaine compound (V-P)
Number of subjects: 150
Study 15970103 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaine
Number of subjects: 150
Study 15970103 — intervention group
Group type: COMPARATOR
Intervention: Control (only glucose)
Number of subjects: 150
Study 12575474 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of citalopram
Number of subjects: 60
Study 12575474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12575474 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg S-adenosyl-L-methionine (SAMe) administered intravenously
Number of subjects: 60
Study 12575474 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard ERP components
Number of subjects: 60
Study 10597810 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral injections of 2% lidocaine solution without epinephrine into the paraglottic space containing the ibSLN
Number of subjects: 9
Study 8589027 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan 1.5 mg/m2 administered intravenously by 30‐minute infusion for 5 days
Number of subjects: 57
Study 2144743 — intervention group
Group type: EXPERIMENTAL
Intervention: Azlocillin plus a long course (at least 9 days) of amikacin
Number of subjects: 0
Study 2144743 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime plus a short course (3 days) of amikacin
Number of subjects: 0
Study 2144743 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime plus a long course of amikacin
Number of subjects: 0
Study 2144743 — intervention group
Group type: EXPERIMENTAL
Intervention: Azlocillin plus amikacin in patients with prolonged and severe neutropenia
Number of subjects: 0
Study 273801 — intervention group
Group type: EXPERIMENTAL
Intervention: ALICE live virus intra-nasal vaccine
Number of subjects: 157
Study 273801 — intervention group
Group type: COMPARATOR
Intervention: Sub-unit vaccine
Number of subjects: 157
Study 273801 — intervention group
Group type: COMPARATOR
Intervention: Placebo intra-nasal vaccine
Number of subjects: 157
Study 31387390 — intervention group
Group type: EXPERIMENTAL
Intervention: Dog-assisted therapy intervention (50-min session per week for 9 months)
Number of subjects: 34
Study 31387390 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 34
Study 31303298 — intervention group
Group type: EXPERIMENTAL
Intervention: Family planning intervention package (refresher training for providers, counselling tool, supportive supervision, availability of contraceptive services 7 days a week, client appointment cards, invitation letters for partners)
Number of subjects: 571
Study 31303298 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 571
Study 31303298 — intervention group
Group type: EXPERIMENTAL
Intervention: Family planning intervention package
Number of subjects: 571
Study 27696447 — intervention group
Group type: EXPERIMENTAL
Intervention: INCS on demand (fluticasone propionate)
Number of subjects: 150
Study 27696447 — intervention group
Group type: COMPARATOR
Intervention: INCS daily (fluticasone propionate)
Number of subjects: 150
Study 27696447 — intervention group
Group type: COMPARATOR
Intervention: Oral antihistamine on demand (levocetirizine)
Number of subjects: 150
Study 26155819 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPLEMENT intervention (two-session interactive workshop with didactic presentations and small group discussions)
Number of subjects: 0
Study 26155819 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence
Number of subjects: 0
Study 23441978 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine 200 mg bid for 21 days with artemether/lumefantrine 80/480 mg from day 8 (3-day course)
Number of subjects: 33
Study 23441978 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir 600/100 mg bid with artemether/lumefantrine 80/480 mg (3-day course)
Number of subjects: 33
Study 23441978 — intervention group
Group type: COMPARATOR
Intervention: Artemether/lumefantrine
Number of subjects: 33
Study 19656815 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor control training
Number of subjects: 25
Study 19656815 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance/strength training
Number of subjects: 25
Study 16708161 — intervention group
Group type: EXPERIMENTAL
Intervention: Red hot chili pepper
Number of subjects: 50
Study 16708161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15056388 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasectomy with fascial interposition
Number of subjects: 841
Study 15056388 — intervention group
Group type: COMPARATOR
Intervention: Vasectomy without fascial interposition
Number of subjects: 841
Study 11563428 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held OBF tonometer
Number of subjects: 35
Study 11563428 — intervention group
Group type: EXPERIMENTAL
Intervention: Slit-lamp mounted OBF tonometer
Number of subjects: 35
Study 11563428 — intervention group
Group type: COMPARATOR
Intervention: Both methods of application
Number of subjects: 35
Study 9029858 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 16
Study 9029858 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminocaproic acid
Number of subjects: 16
Study 8124440 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional brace (the Galveston metacarpal brace)
Number of subjects: 133
Study 8124440 — intervention group
Group type: COMPARATOR
Intervention: Dorsal/ulnar plaster cast
Number of subjects: 133
Study 3314613 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diltiazem 120 to 180 mg
Number of subjects: 10
Study 3314613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29516704 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mcg/kg/h dexmedetomidine in addition to half dose of opioids and benzodiazepines (D-CASEs)
Number of subjects: 48
Study 29516704 — intervention group
Group type: COMPARATOR
Intervention: Standard dose opioids and benzodiazepines (CONTROLs)
Number of subjects: 48
Study 27070409 — intervention group
Group type: COMPARATOR
Intervention: Neuroplasticity-based training program for sensory signal-to-noise resolution, 30 hours over 6 months.
Number of subjects: 0
Study 25271627 — intervention group
Group type: EXPERIMENTAL
Intervention: NYVAC/Ad5hi
Number of subjects: 80
Study 25271627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad5lo/NYVAC
Number of subjects: 80
Study 25271627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad5med/NYVAC
Number of subjects: 80
Study 25271627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad5hi/NYVAC
Number of subjects: 80
Study 25271627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 23103475 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Artery RIsk MAnagement Programme (CARIMAP)
Number of subjects: 168
Study 23103475 — intervention group
Group type: COMPARATOR
Intervention: Usual community care
Number of subjects: 168
Study 20859892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydration with isotonic solution (0.9% NaCl)
Number of subjects: 102
Study 20859892 — intervention group
Group type: COMPARATOR
Intervention: Oral hydration with mineral water
Number of subjects: 102
Study 18098171 — intervention group
Group type: EXPERIMENTAL
Intervention: Angio-Seal VIP
Number of subjects: 200
Study 18098171 — intervention group
Group type: EXPERIMENTAL
Intervention: Perclose Proglide
Number of subjects: 200
Study 18098171 — intervention group
Group type: COMPARATOR
Intervention: Compression
Number of subjects: 200
Study 16647616 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring
Number of subjects: 98
Study 16647616 — intervention group
Group type: COMPARATOR
Intervention: Home blood pressure monitoring
Number of subjects: 98
Study 12844139 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (1 mg/kg) administered intravenously to healthy subjects
Number of subjects: 62
Study 12844139 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (1 mg/kg) administered intravenously to subjects with end-stage renal disease
Number of subjects: 62
Study 12844139 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg) administered subcutaneously to subjects with normal renal function
Number of subjects: 62
Study 12844139 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg) administered subcutaneously to subjects with mildly impaired renal function
Number of subjects: 62
Study 12844139 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg) administered subcutaneously to subjects with moderately impaired renal function
Number of subjects: 62
Study 12844139 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg) administered subcutaneously to subjects with severely impaired renal function
Number of subjects: 62
Study 12844139 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg) administered subcutaneously to subjects with end-stage renal disease
Number of subjects: 62
Study 12844139 — intervention group
Group type: COMPARATOR
Intervention: Dialysis effect on anakinra clearance
Number of subjects: 62
Study 12844139 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between anakinra CL/F and CL(cr)
Number of subjects: 62
Study 10718513 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine infusion
Number of subjects: 0
Study 10718513 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion of saline
Number of subjects: 0
Study 8667466 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose followed by continuous infusion of pralidoxime (16 mg/kg over 30 minutes)
Number of subjects: 7
Study 8667466 — intervention group
Group type: COMPARATOR
Intervention: Short infusion regimen of pralidoxime (4 mg/kg over 15 minutes followed by 3.2 mg/kg/h for 3.75 h)
Number of subjects: 7
Study 1642486 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy enhancement nursing care group
Number of subjects: 156
Study 1642486 — intervention group
Group type: COMPARATOR
Intervention: Routine care group
Number of subjects: 156
Study 6869711 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine 0.2 mg
Number of subjects: 60
Study 6869711 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine 0.4 mg
Number of subjects: 60
Study 6869711 — intervention group
Group type: COMPARATOR
Intervention: Buffered placebo
Number of subjects: 60
Study 31420191 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 6245
Study 31420191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6245
Study 29699527 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (active arm of the InterACT trial)
Number of subjects: 0
Study 29699527 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27171331 — intervention group
Group type: EXPERIMENTAL
Intervention: EMR + RFA
Number of subjects: 0
Study 27171331 — intervention group
Group type: COMPARATOR
Intervention: SRER
Number of subjects: 0
Study 24084496 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg)
Number of subjects: 1024
Study 24084496 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 1024
Study 24084496 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly dosing
Number of subjects: 1024
Study 24084496 — intervention group
Group type: COMPARATOR
Intervention: PRN dosing
Number of subjects: 1024
Study 24084496 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline visual acuity (VA) ≤20/200
Number of subjects: 1024
Study 24084496 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal angiomatous proliferation (RAP)
Number of subjects: 1024
Study 24084496 — intervention group
Group type: EXPERIMENTAL
Intervention: GA in the fellow eye
Number of subjects: 1024
Study 24084496 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraretinal fluid at the foveal center
Number of subjects: 1024
Study 24084496 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked fluorescence
Number of subjects: 1024
Study 24084496 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT measurements of subretinal fluid thickness >25 μ
Number of subjects: 1024
Study 24084496 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal tissue complex thickness >275 μ compared with ≤75 μ
Number of subjects: 1024
Study 24084496 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitreomacular attachment
Number of subjects: 1024
Study 22764542 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine without a vasoconstrictor
Number of subjects: 60
Study 22764542 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with adrenaline (1 : 80.000)
Number of subjects: 60
Study 19106673 — intervention group
Group type: EXPERIMENTAL
Intervention: TEP (totally extraperitoneal patch)
Number of subjects: 1512
Study 19106673 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein
Number of subjects: 1512
Study 17489035 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 561
Study 17489035 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg
Number of subjects: 561
Study 15597171 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Hip Screw (DHS)
Number of subjects: 48
Study 15597171 — intervention group
Group type: COMPARATOR
Intervention: Proximal Femoral Nail (PFN)
Number of subjects: 48
Study 11594447 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine 4 mg twice daily for 14 days
Number of subjects: 12
Study 11594447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9870876 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐1Ra 150 mg/day
Number of subjects: 472
Study 9870876 — intervention group
Group type: COMPARATOR
Intervention: IL‐1Ra
Number of subjects: 472
Study 7672875 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg
Number of subjects: 298
Study 7672875 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam-beta-cyclodextrin equivalent to 20 mg piroxicam
Number of subjects: 298
Study 7672875 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg
Number of subjects: 298
Study 7672875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 2659737 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (3 x 10(6) units)
Number of subjects: 182
Study 2659737 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor (0.5 units)
Number of subjects: 182
Study 2659737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182